drugset

Drugs / PENNVAX-GP

Follow last change May 2021 re-read 2 minutes ago

PENNVAX-GP

Developed for: HIV infectious disease
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

today NCT02431767 · Ph 1

20162017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02431767	Aug 2015 → Jun 2017	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT03606213 Comparator	Aug 2018 → May 2021	HIV infectious disease	Steven Deeks	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	PENNVAX-GP	“PENNVAX-GP HIV DNA vaccine, administered with or without plasmid IL-12 (pIL-12), via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, HIV-uninfected adults.” PMID 32437332 ↗ Jul 2020 2 NCT02431767 ↗ NCT03606213 ↗
Modality	Vaccine	“PENNVAX®-GP HIV-1 DNA vaccine” NCT02431767 ↗
Route	Other	“Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.” NCT03606213 ↗